BeOne Medicines (ONC) Construction in Progress (2016 - 2026)
BeOne Medicines (ONC) posted quarterly Construction in Progress of $137.4 million for Q1 2026, down 76.7% year-over-year from $590.0 million in Q1 2025, and up 8.09% quarter-over-quarter from $127.2 million in Q4 2025.
BeOne Medicines (ONC) Construction in Progress (2016 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Construction in Progress for 10 consecutive years, with $137.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Construction in Progress fell 76.7% year-over-year to $137.4 million; the TTM figure through Mar 2026 stood at $137.4 million (down 76.7% YoY), while the FY2025 annual figure was $127.2 million, down 80.56% from the prior year.
- Construction in Progress climbed to $137.4 million in Q1 2026 per ONC's latest filing, from $127.2 million in the prior quarter.
- Across five years, Construction in Progress topped out at $863.4 million in Q2 2024 and bottomed at $127.2 million in Q4 2025.
- Historically, Construction in Progress has averaged $447.9 million across 5 years, with a median of $430.6 million in 2023.
- Annual changes were most pronounced in 2023 — Construction in Progress jumped 184.02% — and 2025, when it tumbled 80.56%.
- BeOne Medicines' Construction in Progress stood at $293.6 million in 2022, then surged by 152.23% to $740.6 million in 2023, then retreated by 11.69% to $654.0 million in 2024, then sank by 80.56% to $127.2 million in 2025, then increased by 8.09% to $137.4 million in 2026.
- Business Quant data shows ONC's Construction in Progress at $137.4 million in Q1 2026, $127.2 million in Q4 2025, and $129.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 152.67 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 152.67 Mn |
| Mar 31, 2026 | 137.45 Mn |
| Dec 31, 2025 | 127.16 Mn |
| Sep 30, 2025 | 129.12 Mn |
| Jun 30, 2025 | 353.66 Mn |
| Mar 31, 2025 | 589.99 Mn |
| Dec 31, 2024 | 654.02 Mn |
| Sep 30, 2024 | 625.64 Mn |
| Jun 30, 2024 | 863.42 Mn |
| Mar 31, 2024 | 782.86 Mn |
| Dec 31, 2023 | 740.62 Mn |
| Sep 30, 2023 | 631.07 Mn |
| Jun 30, 2023 | 484.31 Mn |
| Mar 31, 2023 | 376.90 Mn |
| Dec 31, 2022 | 293.63 Mn |
| Sep 30, 2022 | 222.19 Mn |
| Mar 31, 2022 | 153.66 Mn |
| Dec 31, 2021 | 186.84 Mn |
| Sep 30, 2021 | 129.36 Mn |
| Jun 30, 2021 | 78.86 Mn |